転移性乳がん治療市場：治療法別、流通チャネル別、地域別、機会、予測、2018年～2032年

世界の転移性乳がん治療の市場規模は、2025年～2032年の予測期間中に11.27％のCAGRで拡大し、2024年の218億米ドルから2032年には512億2,000万米ドルに成長すると予測されています。転移性乳がん治療薬の世界市場は、罹患率の上昇、標的療法の進歩、研究資金の増加により拡大しています。また、認知度の向上と早期診断が治療の普及を促進し、市場関係者にさまざまな市場成長機会を提供しています。さらに、新規薬剤クラスの導入が世界の治療見通しを再構築しています。

例えば、2023年2月、Gilead Sciences, Inc.は、手術不能な局所進行性または転移性乳がんの成人患者を治療するためのトロデルヴィの米国食品医薬品局（FDA）承認を取得しました。この承認は、利用可能な治療の選択肢を増やし、乳がんに苦しむ患者の予後改善につながることが期待されます。

当レポートでは、世界の転移性乳がん治療市場について調査し、市場の概要とともに、治療法別、流通チャネル別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 米国の関税の影響

第4章 エグゼクティブサマリー

第5章 世界の転移性乳がん治療市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
  • 治療法別
    • 化学療法
    • 放射線治療
    • 生物学的標的療法
    • 乳房手術
    • ホルモン療法
  • 流通チャネル別
    • 病院と診療所
    • がんケアセンター
    • 外来手術センター
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 南米
    • 中東・アフリカ
  • 企業別市場シェア分析（上位5社およびその他- 金額別、2024年）
• 2024年の市場マップ分析

第6章 北米の転移性乳がん治療市場の見通し、2018年～2032年

• 市場規模分析と予測
• 市場シェア分析と予測
• 国別市場評価
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の転移性乳がん治療市場の見通し、2018年～2032年

• ドイツ
• フランス
• イタリア
• 英国
• ロシア
• オランダ
• スペイン
• トルコ
• ポーランド

第8章 アジア太平洋の転移性乳がん治療市場の見通し、2018年～2032年

• インド
• 中国
• 日本
• オーストラリア
• ベトナム
• 韓国
• インドネシア
• フィリピン

第9章 南米の転移性乳がん治療市場の見通し、2018年～2032年

• ブラジル
• アルゼンチン

第10章 中東・アフリカの転移性乳がん治療市場の見通し、2018年～2032年

• サウジアラビア
• アラブ首長国連邦
• 南アフリカ

第11章 需要供給分析

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

第14章 PESTLE分析

第15章 価格分析

第16章 市場力学

• 市場の促進要因
• 市場の課題

第17章 市場動向と発展

第18章 規制枠組みとイノベーション

• 規制当局の承認
• 臨床試験

第19章 特許の情勢

第20章 ケーススタディ

第21章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • F. Hoffmann-La Roche Ltd.
  • Pfizer Inc.
  • Jazz Pharmaceuticals Inc.
  • Novartis AG
  • MacroGenics, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Eli Lilly and Company
  • Sun Pharmaceutical Limited
  • Merck & Co.

第22章 戦略的提言

第23章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Global Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 2. Global Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 3. Global Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 4. Global Metastatic Breast Cancer Therapeutics Market Share (%), By Region, 2018-2032F
• Figure 5. North America Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 6. North America Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 7. North America Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 8. North America Metastatic Breast Cancer Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 9. United States Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 10. United States Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 11. United States Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 12. Canada Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 13. Canada Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 14. Canada Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 15. Mexico Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 16. Mexico Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 17. Mexico Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 18. Europe Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 19. Europe Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 20. Europe Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 21. Europe Metastatic Breast Cancer Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 22. Germany Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 23. Germany Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 24. Germany Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 25. France Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 26. France Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 27. France Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 28. Italy Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 29. Italy Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 30. Italy Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 31. United Kingdom Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 32. United Kingdom Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 33. United Kingdom Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 34. Russia Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 35. Russia Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 36. Russia Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 37. Netherlands Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 38. Netherlands Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 39. Netherlands Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 40. Spain Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 41. Spain Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 42. Spain Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 43. Turkey Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 44. Turkey Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 45. Turkey Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 46. Poland Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 47. Poland Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 48. Poland Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 49. South America Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 50. South America Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 51. South America Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 52. South America Metastatic Breast Cancer Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 53. Brazil Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 54. Brazil Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 55. Brazil Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 56. Argentina Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 57. Argentina Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 58. Argentina Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 59. Asia-Pacific Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 60. Asia-Pacific Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 61. Asia-Pacific Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 62. Asia-Pacific Metastatic Breast Cancer Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 63. India Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 64. India Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 65. India Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 66. China Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 67. China Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 68. China Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 69. Japan Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 70. Japan Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 71. Japan Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 72. Australia Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 73. Australia Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 74. Australia Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 75. Vietnam Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 76. Vietnam Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 77. Vietnam Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 78. South Korea Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 79. South Korea Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 80. South Korea Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 81. Indonesia Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 82. Indonesia Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 83. Indonesia Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 84. Philippines Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 85. Philippines Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 86. Philippines Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 87. Middle East & Africa Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 88. Middle East & Africa Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 89. Middle East & Africa Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 90. Middle East & Africa Metastatic Breast Cancer Therapeutics Market Share (%), By Country, 2018-2032F
• Figure 91. Saudi Arabia Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 92. Saudi Arabia Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 93. Saudi Arabia Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 94. UAE Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 95. UAE Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 96. UAE Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 97. South Africa Metastatic Breast Cancer Therapeutics Market, By Value, In USD Billion, 2018-2032F
• Figure 98. South Africa Metastatic Breast Cancer Therapeutics Market Share (%), By Therapy, 2018-2032F
• Figure 99. South Africa Metastatic Breast Cancer Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
• Figure 100. By Therapy Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 101. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 102. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024

Global metastatic breast cancer therapeutics market is projected to witness a CAGR of 11.27% during the forecast period 2025-2032, growing from USD 21.80 billion in 2024 to USD 51.22 billion in 2032. The global metastatic breast cancer therapeutics market is expanding due to rising incidence rates, advancements in targeted therapies, and increased research funding. Growing awareness and early diagnosis are also driving treatment adoption and offering different market growth opportunities to market players. Additionally, the introduction of novel drug classes is reshaping the treatment landscape globally.

For instance, in February 2023, Gilead Sciences, Inc. received the U.S. Food and Drug Administration (FDA) approval for Trodelvy to treat adult patients with inoperable locally advanced or metastatic breast cancer. This approval anticipates enhancing the available treatment choices and likely leads to improved outcomes for patients suffering from breast cancer.

Increasing Prevalence of Metastatic Breast Cancer Globally

The global burden of metastatic breast cancer (MBC) is rising, driven by increasing incidence rates and extended life expectancy. According to the World Health Organization, breast cancer remains the most common cancer among women globally, with a notable portion eventually progressing to the metastatic stage. Improved screening and diagnostic technologies have increased early detection, yet many cases remain undetected until advanced stages, especially in low-resource settings. Additionally, the growing aging population contributes to higher MBC prevalence since age is a significant risk factor. These trends are propelling the demand for effective MBC therapeutics that extend survival and enhance quality of life. Consequently, pharmaceutical companies are boosting R&D efforts to address this unmet need, driving market growth. For instance, in April 2024, Eli Lilly and Company announced plans to expand its breast cancer research program, focusing on metastatic subtypes following a global rise in advanced-stage cases.

Advancements in Biologic Targeted Therapies

The development of biologic targeted therapies has significantly transformed the treatment landscape for metastatic breast cancer. These therapies, designed to target specific genetic markers such as HER2 or hormone receptors, have demonstrated improved efficacy and reduced toxicity compared to traditional chemotherapies. Monoclonal antibodies, antibody-drug conjugates, and small-molecule inhibitors have gained prominence due to their precision in targeting cancer cells while sparing healthy tissue. Biologics not only improve progression-free survival but also open pathways for combination therapies with immunotherapy or hormone therapy. The high success rate in clinical trials and growing approvals from regulatory bodies are accelerating patient access. This trend is expected to boost the global MBC therapeutics market in the coming years. For instance, in October 2023, AstraZeneca plc and Daiichi Sankyo, Inc.'s Enhertu received FDA approval for treating HER2-low metastatic breast cancer, following strong results in the DESTINY-Breast04 trial.

Segmental Growth Driven by Hormone Therapy Adoption

Hormone therapy is a key segment in metastatic breast cancer therapeutics, especially for patients with hormone receptor-positive (HR+) tumors, which constitute a significant share of MBC cases. This therapy works by blocking or lowering estrogen levels to slow down cancer growth. The widespread use of selective estrogen receptor modulators (SERMs), aromatase inhibitors, and estrogen receptor degraders has led to improved disease control with fewer side effects compared to chemotherapy. Additionally, hormone therapies are frequently used as first-line treatments, delaying the need for more aggressive interventions. Recent innovations such as oral SERDs (Selective Estrogen Receptor Degraders) are gaining regulatory attention, further expanding this segment. For instance, in January, 2023, the Food and Drug Administration (FDA) approved elacestrant (Orserdu, Stemline Therapeutics, Inc.) for use in postmenopausal women and adult men diagnosed with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer who have experienced disease progression after at least one line of endocrine therapy. Additionally, the FDA approved the Guardant360 CDx assay as a companion diagnostic tool to help identify breast cancer patients eligible for treatment with elacestrant.

North America Maintains Market Leadership

North America holds the largest share in the metastatic breast cancer therapeutics market, primarily due to the region's well-established healthcare infrastructure, higher awareness levels, and extensive R&D activities. The United States accounts for a significant portion, driven by favorable reimbursement policies, availability of advanced diagnostics, and a strong presence of key pharmaceutical players. Furthermore, government and private sector investments in cancer research and clinical trials have spurred innovation and early market entry for new therapies. The higher prevalence of lifestyle-related risk factors, such as obesity and delayed childbearing, also contributes to the rising incidence, thereby increasing treatment demand. For instance, in November 2023, Truqap (capivasertib) plus Faslodex was approved in the U.S. for patients to cure advanced HR-positive breast cancer.

Future Market Scenario (2025-2032F)

The global metastatic breast cancer therapeutics market is poised for substantial growth due to rising disease incidence, improved diagnostic accuracy, and rapid advancements in precision medicine. Increasing investments in clinical research and the development of targeted therapies, including antibody-drug conjugates and oral selective estrogen receptor degraders, are expanding treatment options and improving patient outcomes. Additionally, the integration of artificial intelligence in drug discovery and personalized medicine approaches is expected to drive innovation. With a growing focus on patient-centric care and expansion of access through online pharmacies and cancer centers, the market is likely to witness accelerated growth globally. Emerging economies, particularly in Asia-Pacific and Latin America, are anticipated to offer lucrative opportunities as healthcare infrastructure and awareness improve.

Key Players Landscape and Outlook

The key players in the market are significantly investing in the development of metastatic breast cancer therapeutics and are utilizing strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness.

Such efforts will propel significant growth in the market, allowing large-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, in 2024, the FDA approved a triple therapy that integrates the small molecule medication inavolisib (Itovebi) with fulvestrant (Faslodex), a hormone treatment, and palbociclib (Ibrance), another small molecule drug, aimed at specific patients suffering from advanced or metastatic HR-positive breast cancer with genetic mutations affecting a protein known as PI3K. Inavolisib inhibits the excessively active variants of PI3K, whereas palbociclib obstructs the functions of the CDK4 and CDK6 proteins, which are responsible for regulating cell growth.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Impact of U.S. Tariffs

4. Executive Summary

5. Global Metastatic Breast Cancer Therapeutics Market Outlook, 2018-2032F

• 5.1. Market Size Analysis & Forecast
  • 5.1.1. By Value
• 5.2. Market Share Analysis & Forecast
  • 5.2.1. By Therapy
    • 5.2.1.1. Chemotherapy
    • 5.2.1.2. Radiation Therapy
    • 5.2.1.3. Biologic Targeted Therapy
    • 5.2.1.4. Breast Surgery
    • 5.2.1.5. Hormone Therapy
  • 5.2.2. By Distribution Channel
    • 5.2.2.1. Hospital and Clinics
    • 5.2.2.2. Cancer Care Centers
    • 5.2.2.3. Ambulatory Surgical Centers
  • 5.2.3. By Region
    • 5.2.3.1. North America
    • 5.2.3.2. Europe
    • 5.2.3.3. Asia-Pacific
    • 5.2.3.4. South America
    • 5.2.3.5. Middle East and Africa
  • 5.2.4. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 5.3. Market Map Analysis, 2024
  • 5.3.1. By Therapy
  • 5.3.2. By Distribution Channel
  • 5.3.3. By Region

6. North America Metastatic Breast Cancer Therapeutics Market Outlook, 2018-2032F

• 6.1. Market Size Analysis & Forecast
  • 6.1.1. By Value
• 6.2. Market Share Analysis & Forecast
  • 6.2.1. By Therapy
    • 6.2.1.1. Chemotherapy
    • 6.2.1.2. Radiation Therapy
    • 6.2.1.3. Biologic Targeted Therapy
    • 6.2.1.4. Breast Surgery
    • 6.2.1.5. Hormone Therapy
  • 6.2.2. By Distribution Channel
    • 6.2.2.1. Hospital and Clinics
    • 6.2.2.2. Cancer Care Centers
    • 6.2.2.3. Ambulatory Surgical Centers
  • 6.2.3. By Country Share
    • 6.2.3.1. United States
    • 6.2.3.2. Canada
    • 6.2.3.3. Mexico
• 6.3. Country Market Assessment
  • 6.3.1. United States Metastatic Breast Cancer Therapeutics Market Outlook, 2018-2032F*
    • 6.3.1.1. Market Size Analysis & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share Analysis & Forecast
      • 6.3.1.2.1. By Therapy
        • 6.3.1.2.1.1. Chemotherapy
        • 6.3.1.2.1.2. Radiation Therapy
        • 6.3.1.2.1.3. Biologic Targeted Therapy
        • 6.3.1.2.1.4. Breast Surgery
        • 6.3.1.2.1.5. Hormone Therapy
      • 6.3.1.2.2. By Distribution Channel
        • 6.3.1.2.2.1. Hospital and Clinics
        • 6.3.1.2.2.2. Cancer Care Centers
        • 6.3.1.2.2.3. Ambulatory Surgical Centers
  • 6.3.2. Canada
  • 6.3.3. Mexico

All segments will be provided for all regions and countries covered

7. Europe Metastatic Breast Cancer Therapeutics Market Outlook, 2018-2032F

• 7.1. Germany
• 7.2. France
• 7.3. Italy
• 7.4. United Kingdom
• 7.5. Russia
• 7.6. Netherlands
• 7.7. Spain
• 7.8. Turkey
• 7.9. Poland

8. Asia-Pacific Metastatic Breast Cancer Therapeutics Market Outlook, 2018-2032F

• 8.1. India
• 8.2. China
• 8.3. Japan
• 8.4. Australia
• 8.5. Vietnam
• 8.6. South Korea
• 8.7. Indonesia
• 8.8. Philippines

9. South America Metastatic Breast Cancer Therapeutics Market Outlook, 2018-2032F

• 9.1. Brazil
• 9.2. Argentina

10. Middle East and Africa Metastatic Breast Cancer Therapeutics Market Outlook, 2018-2032F

• 10.1. Saudi Arabia
• 10.2. UAE
• 10.3. South Africa

11. Demand Supply Analysis

12. Value Chain Analysis

13. Porter's Five Forces Analysis

14. PESTLE Analysis

15. Pricing Analysis

16. Market Dynamics

• 16.1. Market Drivers
• 16.2. Market Challenges

17. Market Trends and Developments

18. Regulatory Framework and Innovation

• 18.1. Regulatory Approvals
• 18.2. Clinical Trials

19. Patent Landscape

20. Case Studies

21. Competitive Landscape

• 21.1. Competition Matrix of Top 5 Market Leaders
• 21.2. SWOT Analysis for Top 5 Players
• 21.3. Key Players Landscape for Top 10 Market Players
  • 21.3.1. F. Hoffmann-La Roche Ltd.
    • 21.3.1.1. Company Details
    • 21.3.1.2. Key Management Personnel
    • 21.3.1.3. Products and Services
    • 21.3.1.4. Financials (As Reported)
    • 21.3.1.5. Key Market Focus and Geographical Presence
    • 21.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 21.3.2. Pfizer Inc.
  • 21.3.3. Jazz Pharmaceuticals Inc.
  • 21.3.4. Novartis AG
  • 21.3.5. MacroGenics, Inc.
  • 21.3.6. AstraZeneca plc
  • 21.3.7. Bayer AG
  • 21.3.8. Eli Lilly and Company
  • 21.3.9. Sun Pharmaceutical Limited
  • 21.3.10. Merck & Co.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

22. Strategic Recommendations

23. About Us and Disclaimer